Polyestradiol phosphate

DB09369

small molecule approved

Deskripsi

Polymeric phosphoric acid ester of estradiol.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

549 Data
Prasterone The risk or severity of adverse effects can be increased when Prasterone is combined with Polyestradiol phosphate.
Exemestane The therapeutic efficacy of Exemestane can be decreased when used in combination with Polyestradiol phosphate.
Hyaluronidase (ovine) The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Polyestradiol phosphate.
Hyaluronidase (human recombinant) The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Polyestradiol phosphate.
Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Polyestradiol phosphate.
Lenalidomide Polyestradiol phosphate may increase the thrombogenic activities of Lenalidomide.
Ospemifene The risk or severity of adverse effects can be increased when Polyestradiol phosphate is combined with Ospemifene.
Ropinirole Polyestradiol phosphate may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.
Thalidomide Polyestradiol phosphate may increase the thrombogenic activities of Thalidomide.
Cetuximab Polyestradiol phosphate may increase the thrombogenic activities of Cetuximab.
Human immunoglobulin G Polyestradiol phosphate may increase the thrombogenic activities of Human immunoglobulin G.
Omalizumab Polyestradiol phosphate may increase the thrombogenic activities of Omalizumab.
Adalimumab Polyestradiol phosphate may increase the thrombogenic activities of Adalimumab.
Gemtuzumab ozogamicin Polyestradiol phosphate may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Indium In-111 satumomab pendetide Polyestradiol phosphate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Infliximab Polyestradiol phosphate may increase the thrombogenic activities of Infliximab.
Trastuzumab Polyestradiol phosphate may increase the thrombogenic activities of Trastuzumab.
Rituximab Polyestradiol phosphate may increase the thrombogenic activities of Rituximab.
Basiliximab Polyestradiol phosphate may increase the thrombogenic activities of Basiliximab.
Muromonab Polyestradiol phosphate may increase the thrombogenic activities of Muromonab.
Digoxin Immune Fab (Ovine) Polyestradiol phosphate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Ibritumomab tiuxetan Polyestradiol phosphate may increase the thrombogenic activities of Ibritumomab tiuxetan.
Tositumomab Polyestradiol phosphate may increase the thrombogenic activities of Tositumomab.
Alemtuzumab Polyestradiol phosphate may increase the thrombogenic activities of Alemtuzumab.
Capromab pendetide Polyestradiol phosphate may increase the thrombogenic activities of Capromab pendetide.
Efalizumab Polyestradiol phosphate may increase the thrombogenic activities of Efalizumab.
Antithymocyte immunoglobulin (rabbit) Polyestradiol phosphate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Natalizumab Polyestradiol phosphate may increase the thrombogenic activities of Natalizumab.
Palivizumab Polyestradiol phosphate may increase the thrombogenic activities of Palivizumab.
Daclizumab Polyestradiol phosphate may increase the thrombogenic activities of Daclizumab.
Bevacizumab Polyestradiol phosphate may increase the thrombogenic activities of Bevacizumab.
Technetium Tc-99m arcitumomab Polyestradiol phosphate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Eculizumab Polyestradiol phosphate may increase the thrombogenic activities of Eculizumab.
Panitumumab Polyestradiol phosphate may increase the thrombogenic activities of Panitumumab.
Ranibizumab Polyestradiol phosphate may increase the thrombogenic activities of Ranibizumab.
Galiximab Polyestradiol phosphate may increase the thrombogenic activities of Galiximab.
Pexelizumab Polyestradiol phosphate may increase the thrombogenic activities of Pexelizumab.
Afelimomab Polyestradiol phosphate may increase the thrombogenic activities of Afelimomab.
Epratuzumab Polyestradiol phosphate may increase the thrombogenic activities of Epratuzumab.
Bectumomab Polyestradiol phosphate may increase the thrombogenic activities of Bectumomab.
Oregovomab Polyestradiol phosphate may increase the thrombogenic activities of Oregovomab.
IGN311 Polyestradiol phosphate may increase the thrombogenic activities of IGN311.
Adecatumumab Polyestradiol phosphate may increase the thrombogenic activities of Adecatumumab.
Labetuzumab Polyestradiol phosphate may increase the thrombogenic activities of Labetuzumab.
Matuzumab Polyestradiol phosphate may increase the thrombogenic activities of Matuzumab.
Fontolizumab Polyestradiol phosphate may increase the thrombogenic activities of Fontolizumab.
Bavituximab Polyestradiol phosphate may increase the thrombogenic activities of Bavituximab.
CR002 Polyestradiol phosphate may increase the thrombogenic activities of CR002.
Rozrolimupab Polyestradiol phosphate may increase the thrombogenic activities of Rozrolimupab.
Girentuximab Polyestradiol phosphate may increase the thrombogenic activities of Girentuximab.
Obiltoxaximab Polyestradiol phosphate may increase the thrombogenic activities of Obiltoxaximab.
XTL-001 Polyestradiol phosphate may increase the thrombogenic activities of XTL-001.
NAV 1800 Polyestradiol phosphate may increase the thrombogenic activities of NAV 1800.
Briakinumab Polyestradiol phosphate may increase the thrombogenic activities of Briakinumab.
Otelixizumab Polyestradiol phosphate may increase the thrombogenic activities of Otelixizumab.
AMG 108 Polyestradiol phosphate may increase the thrombogenic activities of AMG 108.
Iratumumab Polyestradiol phosphate may increase the thrombogenic activities of Iratumumab.
Enokizumab Polyestradiol phosphate may increase the thrombogenic activities of Enokizumab.
Ramucirumab Polyestradiol phosphate may increase the thrombogenic activities of Ramucirumab.
Farletuzumab Polyestradiol phosphate may increase the thrombogenic activities of Farletuzumab.
Veltuzumab Polyestradiol phosphate may increase the thrombogenic activities of Veltuzumab.
Ustekinumab Polyestradiol phosphate may increase the thrombogenic activities of Ustekinumab.
Trastuzumab emtansine Polyestradiol phosphate may increase the thrombogenic activities of Trastuzumab emtansine.
PRO-542 Polyestradiol phosphate may increase the thrombogenic activities of PRO-542.
TNX-901 Polyestradiol phosphate may increase the thrombogenic activities of TNX-901.
Inotuzumab ozogamicin Polyestradiol phosphate may increase the thrombogenic activities of Inotuzumab ozogamicin.
RI 624 Polyestradiol phosphate may increase the thrombogenic activities of RI 624.
Stamulumab Polyestradiol phosphate may increase the thrombogenic activities of MYO-029.
CT-011 Polyestradiol phosphate may increase the thrombogenic activities of CT-011.
Leronlimab Polyestradiol phosphate may increase the thrombogenic activities of Leronlimab.
Glembatumumab vedotin Polyestradiol phosphate may increase the thrombogenic activities of Glembatumumab vedotin.
Olaratumab Polyestradiol phosphate may increase the thrombogenic activities of Olaratumab.
IPH 2101 Polyestradiol phosphate may increase the thrombogenic activities of IPH 2101.
TB-402 Polyestradiol phosphate may increase the thrombogenic activities of TB-402.
Caplacizumab Polyestradiol phosphate may increase the thrombogenic activities of Caplacizumab.
IMC-1C11 Polyestradiol phosphate may increase the thrombogenic activities of IMC-1C11.
Eldelumab Polyestradiol phosphate may increase the thrombogenic activities of Eldelumab.
Lumiliximab Polyestradiol phosphate may increase the thrombogenic activities of Lumiliximab.
Canakinumab Polyestradiol phosphate may increase the thrombogenic activities of Canakinumab.
Ipilimumab Polyestradiol phosphate may increase the thrombogenic activities of Ipilimumab.
Nimotuzumab Polyestradiol phosphate may increase the thrombogenic activities of Nimotuzumab.
Clenoliximab Polyestradiol phosphate may increase the thrombogenic activities of Clenoliximab.
Tocilizumab Polyestradiol phosphate may increase the thrombogenic activities of Tocilizumab.
BIIB015 Polyestradiol phosphate may increase the thrombogenic activities of BIIB015.
Sonepcizumab Polyestradiol phosphate may increase the thrombogenic activities of Sonepcizumab.
Motavizumab Polyestradiol phosphate may increase the thrombogenic activities of Motavizumab.
Elotuzumab Polyestradiol phosphate may increase the thrombogenic activities of Elotuzumab.
AVE9633 Polyestradiol phosphate may increase the thrombogenic activities of AVE9633.
Carotuximab Polyestradiol phosphate may increase the thrombogenic activities of Carotuximab.
XmAb 2513 Polyestradiol phosphate may increase the thrombogenic activities of XmAb 2513.
Coltuximab ravtansine Polyestradiol phosphate may increase the thrombogenic activities of Coltuximab ravtansine.
Lucatumumab Polyestradiol phosphate may increase the thrombogenic activities of Lucatumumab.
Pertuzumab Polyestradiol phosphate may increase the thrombogenic activities of Pertuzumab.
Siplizumab Polyestradiol phosphate may increase the thrombogenic activities of Siplizumab.
Apolizumab Polyestradiol phosphate may increase the thrombogenic activities of Apolizumab.
Sibrotuzumab Polyestradiol phosphate may increase the thrombogenic activities of Sibrotuzumab.
Bivatuzumab Polyestradiol phosphate may increase the thrombogenic activities of Bivatuzumab.
Lerdelimumab Polyestradiol phosphate may increase the thrombogenic activities of Lerdelimumab.
Lexatumumab Polyestradiol phosphate may increase the thrombogenic activities of Lexatumumab.
Reslizumab Polyestradiol phosphate may increase the thrombogenic activities of Reslizumab.

Target Protein

Estrogen receptor ESR1

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Estradurin

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul